Financial Information

Capital Market Release


PTA-AFR: Dr. Hönle AG: Pre-announcement of a financial report according to articles 114 - 117 WpHG

18.04.2024

Gilching (pta028/18.04.2024/15:30) - Dr. Hönle AG announces that the following financial reports shall be disclosed:

read more ...

 

PTA-PVR: Dr. Hönle AG: Release according to Article 40, Section 1 of the WpHG

27.02.2024

Gilching (pta019/27.02.2024/10:45) - Release of Voting Rights Announcement

read more ...

 

PTA-News: Dr. Hönle AG: Hönle Group has a moderate start to the new financial year and confirms the outlook for the year as a whole

26.02.2024

Gilching (pta006/26.02.2024/07:55) - * Revenue in the first quarter of €23.8 million below the previous year's figure of €27.6 million due to the weak market environment * Operating result of € -0.8 million after € 1.9 million in the previous year * Positive operating cash flow of...

read more ...

 

Adhoc Release


PTA-Adhoc: Dr. Hönle AG: Hönle Group expects a decline in sales and earnings in Q1 and confirms outlook for the financial year

09.02.2024

Gilching (pta007/09.02.2024/08:30) - The Hönle Group achieved lower sales and results in the first three months of the 2023/2024 financial year compared to the period of the previous year due to the weak market environment in machinery and plant engineering as well as order delays.

read more ...

 

PTA-Adhoc: Dr. Hönle AG: Hönle Group adjusts forecast for the 2022/2023 FY and provides outlook on the 2023/2024 FY

05.12.2023

Gilching (pta044/05.12.2023/20:00) - The Management Board expected for the Hönle Group, sales of €100 million to €105 million, an adjusted operating result (EBIT adjusted) of €5.5 million to €6.5 million and an operating result (EBIT ) between €7 million and €8 million in the...

read more ...

 

PTA-Adhoc: Dr. Hönle AG: Dr. Markus Arendt becomes Managing Director of Dr. Hönle AG

20.10.2023

Gilching (pta022/20.10.2023/17:35) - The Supervisory Board of Dr. Hönle AG intends to appoint Dr. Markus Arendt as a member of the Management Board of Dr. Hönle AG with effect presumably from May 1st, 2024. He will follow Dr. Franz Richter, who was delegated to the Management Board by...

read more ...

 

Find more Articles in our archives.

Archives

 

 

Facts & Figures

Sales Revenues Hönle Group: till 98/99: "as-if"-accounts
EBIT Hönle Group: till 98/99: "as-if"-account, since 04/05: "share-based" payment according to IFRS2
Net Profit Hönle Group: till 98/99: "as-if"-accounts before results shares of that atypical allay shareholder, since 04/04: "share-based" payment according IFRS2
Number of Employees in the Hönle Group:  data at the end of fiscal year, without board of directors

 

7 Good Reasons

  1. Leading Market Position
  2. Expansion in Existing Markets
  3. Technological Lead
  4. Hönle as a Process Accelerator
  5. Expansion in Growth Markets
  6. Internationalization
  7. Strong Partners
show more

1. Leading Market Position

Dr. Hönle AG is among the global leaders in the area of UV technology for industrial applications. We are a pace setter in UV technology and in the development of new applications. Our clientele stands for competence and innovation capability. Our customers include leading companies from all target industries. Manroland, Durst, Philips and Krones are working with Hönle equipment.


2. Expansion in Existing Markets

We utilize the benefits of industrial UV technology in the optimization of many production processes in the most diverse of industries. Thus, for example the use of UV-reactive colours yields significant time savings and the production of first-class end products. The 100% solvent-free paints and varnishes do not pose any hazards to humans and the environment. This is why traditional production processes are increasingly being replaced by UV-reactive methods.


3. Technological Lead

The number of UV applications is rapidly expanding and the technology is entering an increasing field of applications. Hönle has launched a completely new device for DVD production. We not only continue to develop established technologies but are also setting standards for tapping new application fields in close cooperation with other companies, universities and research institutes.


4. Hönle as a Process Accelerator

The use of UV systems can simplify production processes, raise productivity and enable direct further processing. This simplifies just in time deliveries and thus provides our customers with an important competitive advantage.


5. Expansion in Growth Markets

Industrial adhesives and UV-based digital printing are areas in which our technology plays an increasingly important role. The environmentally friendly sterilization of water also is an important growth market. We will continue to intensify our activities in these fields.


6. Internationalization

Hönle has an international distribution network, which gives us a worldwide presence in close proximity to our customers. In particular, the strong European position provides us with a solid foundation for our continued dynamic internationalization, primarily in the US and Asia. The export shart is more than 50%.


7. Strong Partners

Development partnerships with leading companies, such as in the printing industry, the photovoltaic industry or the consumer electronics business form the foundation for our technological lead. With the development of new methods we ensure our development leadership and mutually benefit from the exchange of experience.

 

show less

Reports & Presentation

Disclaimer

The articles and analyses published on our web pages are intended only for informational purposes and do not represent offers for the purchase or selling of securities or other investment instruments. The present data are compiled to the best of our knowledge and in good faith. With regard to future-related statements neither Dr. Hönle AG nor any of the associated companies can assume responsibility for the occurrence of the forecast. Due to changing general economic conditions or other factors beyond the control of Dr. Hönle AG, future results may differ considerably from the forecast. Irrespective of legal obligations for adjusting forecasts, Dr. Hönle AG does not intend to continually update all statements related to the future.